



HR0156

LRB100 10139 MST 21975 r

1

HOUSE RESOLUTION

2

WHEREAS, Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell growth of the arterial wall; it can lead to areas of narrowing, beading, aneurysms, and dissections of the arterial wall; and

3

4

5

6

WHEREAS, Until recently, there has been very little progress in understanding the disease since it was first diagnosed in 1938; there is no known cause or cure for the disease and there are no set protocols to treat the disease; and

7

8

9

10

11

WHEREAS, FMD has always been considered and is still classified as a rare disease; many researchers now believe FMD is an under-diagnosed disease; some of the data suggest that 4-5% of the population may be affected by the disease; and

12

13

14

15

WHEREAS, Ninety percent of the patients affected by FMD are women, but men and children are also afflicted; there are different classifications of FMD; the two most common types are medial fibroplasia and intimal fibroplasia; unlike the adult population, children tend to be diagnosed with intimal fibroplasia, which can be more aggressive; some patients present with both types of the disease; there is no understanding of why there are differences; and

16

17

18

19

20

21

22

1           WHEREAS, Individuals and families affected by  
2 fibromuscular dysplasia often experience problems such as a  
3 sense of isolation, difficulty in obtaining accurate and timely  
4 diagnosis, and optimal treatment options; and

5           WHEREAS, The Fibromuscular Dysplasia Society of America  
6 (FMDSA) was founded in March of 2003; over the past 14 years,  
7 this association has been active and successful with many  
8 programs, including public and physician awareness, patient  
9 support, and engaging with researchers from around the world;  
10 and

11           WHEREAS, The FMDSA is funding the United States Registry  
12 for Fibromuscular Dysplasia; previously it was thought that 75%  
13 of FMD cases affected the renal arteries, but recent data has  
14 proven that to be inaccurate; it is also very common to have a  
15 5-year delay from onset of symptoms to diagnosis; and

16           WHEREAS, There is still much needed awareness and research  
17 of the disease; FMD patients present with many of the same  
18 complaints as other patients with more common conditions, such  
19 as hypertension, headaches, and dizziness; others present with  
20 TIA or stroke, dissection of an artery, aneurysm, swooshing  
21 noise in the ear, and renal infarction; children can present  
22 with basic symptoms such as high blood pressure, headaches,

1 insomnia, fatigue, and abdominal pain; misdiagnoses of FMD can  
2 lead to severe consequences and disability; and

3 WHEREAS, During the month of May each year, the FMDSA  
4 organizes a global observance of the issues associated with  
5 fibromuscular dysplasia; patients, medical professionals, and  
6 researchers join together to focus attention on fibromuscular  
7 dysplasia as a public health issue; therefore, be it

8 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE  
9 HUNDREDTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we  
10 designate May of 2017 as "Fibromuscular Dysplasia Awareness  
11 Month" in the State of Illinois; and be it further

12 RESOLVED, That a suitable copy of this resolution be  
13 presented to the Fibromuscular Dysplasia Society of America as  
14 an expression of our esteem and respect.